[SCItalk] Inhibitor of Differentiation 1 Targeting in the Treatment of Lung Cancer
Universidad de Navarra, Spain
Prof. Gil-Bazo is the Chairman of the Department of Oncology at the University of Navarra, in Pamplona. In addition, he is Associate Professor of Medicine at the Department of Oncology at the University of Navarra School of Medicine and Director of the Predictive Markers of Response Laboratory of the Program in Solid Tumors at the Center for Applied Medical Research (CIMA). Prof. Gil-Bazo is a Medical Oncologist with extensive expertise in Thoracic Oncology, Translational Research in Oncology and Clinical Investigation.
Prof. Gil-Bazo graduated with a degree in Medicine from the University of Navarra, Spain in 1999. He obtained a PhD in Experimental and Clinical Oncology Research cum laude from the University of Navarra, in 2004. He was awarded the National Annual Research Fellowship by the Nacional Spanish Center for Oncology Research (CNIO) and the Best National Doctoral Thesis in Medicine Award.
From 2004 to 2006, Prof. Gil-Bazo joined the Cancer Biology and Genetics Program at Memorial Sloan-Kettering Cancer Center in New York, NY, USA, and worked under the supervision of Prof. Joan Massagué in Dr. Benezra’s Laboratory. Since 2006, Prof. Gil-Bazo has led the lung cancer clinical research program at the University of Navarra and served as principal investigator in more than 25 phase I-III clinical trials and sub-investigator in more than other 30 with a special interest in targeted therapies and immunotherapy.
Prof. Gil-Bazo is a member of the International Association for the Study of Lung Cancer (IASLC) and has served as faculty as well as a mentor for the IASLC Academy. He currently leads the Predictive Markers of Response Laboratory at the Center for Applied Medical Research (CIMA) and his research has been uninterruptedly funded since 2006 by private and public agencies. His team has pioneered the research trying to unravel the role of inhibitor of differentiation genes in lung cancer. His clinical and translational research has produced more than 90 papers published in peer-reviewed journals.
Host: Ernest Nadal